The purpose of these trials is to assess mRNA vaccines for their potential to lower pro-inflammatory cytokines such as IL-1β and TNF-α, which are known to promote plaque progression, as well as LDL-C, a major driver of atherosclerosis. Here, TNF is linked to atherosclerosis.